Press releases

To stay up to date with our development, sign up for a subscription.

Subscribe

First patient enrolled in SESAR study on lung protection

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that that the first patient has been included in SESAR, the world's largest multicenter study with AnaConDa to evaluate whether inhaled sedation via AnaConDa has lung-protective properti…

Notice of Annual General Meeting in Sedana Medical AB (publ)

Regulatory

The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting on Tuesday 19 May 2020 at 4:00 p.m. (CEST) at Konferens Spårvagnshallarna, Birger Jarlsgatan 57 A in Stockholm. Registrat…

Sedana Medical's sales increase around 90 percent

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company expects sales of approximately SEK 34 million in the first quarter of 2020, corresponding to growth of around 90 percent compared to the same period last year.

Sedana Medical sees increased demand and keeps time schedule

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company sees increased demand for AnaConDa as a result of the Covid-19 pandemic and so far, has had no significant supply chain disruptions. Sedana Medical forecasts a sales inc…

Sedana Medical Research Grant 2020 open for applications

Non-regulatory

Sedana Medical AB (publ) today announced the opening for researchers to apply for Sedana Medical Research Grant 2020. The grant creates a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill pa…

Sedana Medical donates AnaConDa to hospitals in Wuhan, China

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company is donating the medical device AnaConDa and accessories for anti-epidemic use and evaluation of the effects of inhalation sedation with AnaConDa on severely ill Corona v…

Sedana Medical establishes sales organization in Benelux

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has set up its own direct sales organization in Benelux, in line with the strategy of being represented in several European markets in order to have well-established net…

Sedana Medical receives approval for AnaConDa in Mexico

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has obtained market approval for AnaConDa in Mexico. Sedana Medical's Mexican distributor Goba will begin sales work in the next few months and in parallel Sedana will e…

Last patient included in Sedana Medical's pivotal IsoConDa study

Non-regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the last patient has now been included in the pivotal IsoConDa study. Thus, all 300 patients have been included and the study is expected to show top-line results during Q2 2020.

Sedana Medical adjusts and clarifies its long-term financial targets

Regulatory

Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company will no longer communicate a profit target for the period until registration of IsoConDa in Europe. It also clarifies the sales target of SEK 500 million three years aft…